Haemonetics 

€65.50
0
-€1.00-1.5% 今天

統計

當日最高
65.5
當日最低
65.5
52週高點
73.5
52週低點
40.2
成交量
-
平均成交量
-
市值
0
本益比
-
股息殖利率
-
股息
-

即將到來

財報

11Aug預期
Q4 2025
Q1 2026
下一步
0.94
1
1.05
1.11
預期EPS
0.9370415174
實際EPS
不適用

其他人也在關注

此清單是根據在 Stock Events 上追蹤 HAZ.STU 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Show more...
執行長
Mr. Christopher A. Simon
員工
3009
國家
德國
ISIN
US4050241003

上市

0 Comments

分享你的想法

FAQ

Haemonetics 今天的股價是多少?
HAZ.STU 目前價格為 €65.50 EUR,過去 24 小時下跌了 -1.5%。在圖表上更密切關注 Haemonetics 股票的表現。
Haemonetics 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Haemonetics 的股票以代號 HAZ.STU 進行交易。
Haemonetics 的股價在上漲嗎?
HAZ.STU 股票較上週上漲 +0.77%,本月上漲 +35.33%,過去一年 Haemonetics 上漲 +10.08%。
Haemonetics 下一次財報日期是什麼時候?
Haemonetics 將於 August 11, 2026 公布下一次財報。
Haemonetics 上一季度的財報如何?
HAZ.STU 上一季度的財報為每股 1.1 EUR,預估為 1.09 EUR,帶來 +1.36% 的驚喜。下一季度的預估財報為每股 不適用 EUR。
Haemonetics 有多少名員工?
截至 June 16, 2026,公司共有 3,009 名員工。
Haemonetics 位於哪個產業?
Haemonetics從事於Health & Wellness產業。
Haemonetics 何時完成拆股?
Haemonetics 上次拆股發生於 December 03, 2012,比例為 2:1。
Haemonetics 的總部在哪裡?
Haemonetics 的總部位於 德國 的 Boston。